Apple Inc ((AAPL)), Apple Inc (($CC:AAPL.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Apple Inc. (AAPL) has collaborated with Janssen Scientific Affairs, LLC, to complete a clinical study titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study aims to identify and diagnose Atrial Fibrillation (AF), improve cardiovascular outcomes, enhance adherence to direct oral anti-coagulants, and identify predictors of the disease.
The study tested two interventions using the Apple Watch Series 5 or later. The ‘Heart healthy Engagement Program’ targeted participants without AF, while the ‘Anti-Coagulation Adherence Module’ focused on those with AF, aiming to improve health outcomes through digital engagement.
Conducted as an observational cohort study with a prospective time perspective, participants were divided into groups based on their AF status and randomly assigned to either an Apple Watch/iPhone group or an iPhone-only group.
The study began on February 25, 2020, and was recently updated on July 17, 2025. The completion of this study marks a significant milestone in leveraging digital technology for heart health.
This update could positively influence Apple’s stock performance by showcasing the company’s commitment to health innovation, potentially enhancing investor sentiment. As the tech industry increasingly intersects with healthcare, Apple’s advancements may set a competitive benchmark.
The study is now completed, with further details available on the ClinicalTrials portal.